{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:46Z","timestamp":1789726246224,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s40264-017-0634-y","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T13:44:48Z","timestamp":1515764688000},"page":"515-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Series Analysis of New Zealand Reports of Rapid Intense Potentiation of Warfarin by Roxithromycin"],"prefix":"10.1007","volume":"41","author":[{"given":"Ruth L.","family":"Savage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Tatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"634_CR1","unstructured":"Drugdex. Roxithromycin. \n                    http:\/\/www.micromedexsolutions.com\n                    \n                  . Accessed 21 Dec 2017."},{"key":"634_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1600-0773.1988.tb00943.x","volume":"63","author":"O Paulsen","year":"1988","unstructured":"Paulsen O, Nilsson L, Saint-Salvi B, et al. No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin and its enantiomers. Pharmacol Toxicol. 1988;63:215\u201320.","journal-title":"Pharmacol Toxicol"},{"key":"634_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.2165\/00044011-199510050-00008","volume":"10","author":"K Ghose","year":"1995","unstructured":"Ghose K, Ashton J, Rohan A. Possible interaction of roxithromycin with warfarin: updated review of ADR reports. Clin Drug Investig. 1995;10:302\u20139.","journal-title":"Clin Drug Investig."},{"key":"634_CR4","first-page":"1053","volume":"26","author":"H Yamazaki","year":"1998","unstructured":"Yamazaki H, Shimada T. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6b-hydroxylation by roxithromycin and its metabolites, trolandeomycin and erythromycin. Drug Metab Dispos. 1998;26:1053\u20137.","journal-title":"Drug Metab Dispos"},{"key":"634_CR5","unstructured":"The Centre for Adverse Reactions Monitoring. Dunedin: University of Otago; 2017. \n                    http:\/\/nzphvc.otago.ac.nz\n                    \n                  . Accessed 11 Dec 2017."},{"key":"634_CR6","unstructured":"Medsafe. Suspected Medication Adverse Reactions Search (SMARS). Medsafe; 2017. \n                    http:\/\/www.medsafe.govt.nz\/Projects\/B1\/ADRDisclaimer.asp\n                    \n                  . Accessed 6 Nov 2017."},{"key":"634_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/jppr.1093","volume":"45","author":"J-A Rotella","year":"2015","unstructured":"Rotella J-A, Taylor DM. Concomitant roxithromycin use amongst elderly patients taking warfarin resulting in significant over-anticoagulation. J Pharm Pract Res. 2015;45:182\u20135.","journal-title":"J Pharm Pract Res."},{"key":"634_CR8","unstructured":"Medsafe editorial team. Watching briefs. Roxithromycin-warfarin interaction of increased INR. Prescriber update 2008; 29:2. \n                    http:\/\/www.medsafe.govt.nz\/profs\/PUArticles\/watchingbriefsMay08.htm#Roxithromycin\n                    \n                  . Accessed 10 Jun 2017."},{"key":"634_CR9","unstructured":"Stockley\u2019s interaction alerts. \n                    http:\/\/nzf.org.nz\/interactions\/stockleys\/of\/10249701000116101\n                    \n                  . Accessed 30 Sep 2017."},{"key":"634_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1046\/j.1365-2141.1998.00988.x","volume":"103","author":"S Panneerselvam","year":"1998","unstructured":"Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol. 1998;103:422\u20134.","journal-title":"Br J Haematol"},{"key":"634_CR11","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11606-005-0113-5","volume":"20","author":"JJ Glasheen","year":"2005","unstructured":"Glasheen JJ, Fugit RV, Prochazka AV. The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J Gen Intern Med. 2005;20:653\u20136.","journal-title":"J Gen Intern Med"},{"key":"634_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR Database System: basic facts. Drug Inf J. 2008;42:409\u201319.","journal-title":"Drug Inf J."},{"key":"634_CR13","first-page":"7","volume":"25","author":"ADRAC","year":"2006","unstructured":"ADRAC. Interactions with macrolides. Aust Adv Drug React Bull. 2006;25:7\u20138.","journal-title":"Aust Adv Drug React Bull"},{"key":"634_CR14","unstructured":"Rochon PA, Schmader KE, Sullivan DJ. Drug prescribing for older adults. 26 May 2017. \n                    http:\/\/www.uptodate.com\/contents\/drug-prescribing-for-older-adults\n                    \n                  . Accessed 20 Sep 2017."},{"key":"634_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2141.2011.08753.x","volume":"154","author":"D Keeling","year":"2011","unstructured":"Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. British committee for standards in haematology. Br J Haematol. 2011;154:311\u201324.","journal-title":"Br J Haematol"},{"key":"634_CR16","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1160\/TH04-02-0083","volume":"91","author":"HV Joffe","year":"2004","unstructured":"Joffe HV, Xu R, Bradley Johnson F, et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost. 2004;91:1123\u20138.","journal-title":"Thromb Haemost."},{"issue":"2 Suppl.","key":"634_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1378\/chest.11-2295","volume":"141","author":"A Holbrook","year":"2012","unstructured":"Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl.):152\u201384.","journal-title":"Chest"},{"key":"634_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamainternmed.2013.13957","volume":"174","author":"NP Clark","year":"2014","unstructured":"Clark NP, Delate T, Riggs CS, et al. Warfarin interactions with antibiotics in the ambulatory care setting. JAMA Intern Med. 2014;174:409\u201316.","journal-title":"JAMA Intern Med."},{"key":"634_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.amjmed.2011.08.014","volume":"125","author":"J Baillargeon","year":"2012","unstructured":"Baillargeon J, Holmes HM, Lin Y-L, Raji MA, Sharma G, Kuo Y-F. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med. 2012;125:183\u20139.","journal-title":"Am J Med"},{"key":"634_CR20","unstructured":"Sanofi-Aventis, France. Rulid. 23 May 2017. \n                    http:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid=65393957&typedoc=R\n                    \n                  . Accessed 15 Sep 2017."},{"key":"634_CR21","unstructured":"Sanofi AB. Surlid. 2 July 2017. \n                    http:\/\/www.fass.se\/LIF\/product?3&userType=0&nplId=19900405000019&docType=6\n                    \n                  . Accessed 15 Sep 2017."},{"key":"634_CR22","unstructured":"Teva Pharma New Zealand. Arrow-Roxithromycin. 10 Feb 2017. \n                    http:\/\/www.medsafe.govt.nz\/profs\/datasheet\/a\/ArrowRoxithromycintab.pdf\n                    \n                  . Accessed 15 Sep 2017."},{"key":"634_CR23","unstructured":"Sanofi-Aventis New Zealand Ltd. Rulide. 8 Sep 2017. \n                    http:\/\/www.medsafe.govt.nz\/profs\/Datasheet\/r\/rulideDtab.pdf\n                    \n                  . Accessed 15 Sep 2017."},{"key":"634_CR24","unstructured":"Sanofi-Aventis Australia Pty Ltd. Rulide. 21 Jan 2015. \n                    http:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-PI-06117-3&d=2016050416114622483\n                    \n                  . Accessed 15 Sep 2017."},{"key":"634_CR25","unstructured":"Medsafe editorial team. Check INR after starting roxithromycin for patients on warfarin. Prescriber update. 2015; 36:3. \n                    http:\/\/www.medsafe.govt.nz\/profs\/PUArticles\/March2015Roxithromycin.htm\n                    \n                  . Accessed 10 Jun 2017."},{"key":"634_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jppr.1142","volume":"45","author":"A Thompson","year":"2015","unstructured":"Thompson A. Concomitant roxithromycin use amongst elderly patients taking warfarin resulting in significant over-anticoagulation (letter to the editor). J Pharm Pract Res. 2015;45:486.","journal-title":"J Pharm Pract Res."},{"key":"634_CR27","unstructured":"BPACnz. The 2017 bpacnz antibiotic guide: choices for common infections. \n                    www.bpac.org.nz\/antibiotics\/guide.aspx\n                    \n                  . Accessed 16 Sep 2017."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0634-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0634-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0634-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T01:47:36Z","timestamp":1547257656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0634-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0634-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,12]]},"assertion":[{"value":"12 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist in the preparation of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ruth L. Savage and Michael V. Tatley have no conflicts of interest directly relevant to the content of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The researchers are members of the New Zealand national adverse drug reaction monitoring service who performed this analysis based on observations arising from routine review of voluntary adverse reaction reports submitted to the New Zealand pharmacovigilance database. Ethical approval is not required for national pharmacovigilance database review activities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}